Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
CAS No. | 216974-75-3 |
---|---|
Formulation | PBS buffer, pH 7.2 |
Isotype | Human IgG1 |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Purity | 99.4% |
Protein concentration | 5mg/ml |
Endotoxin Level | ≤1 EU/mg |
Description | Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD. | |||
---|---|---|---|---|
Targets |
|
|||
In vitro | Blocking VEGF with bevacizumab reduces the proangiogenic effect of affected fibroblasts in both the matrigel and direct coculture angiogenesis models.[1] |
|||
In vivo | The combinational treatment of AAV9-LECT2-shRNA and bevacizumab significantly improves the therapeutic effects on liver fibrosis.[2] |
Cell Assay: |
|
---|---|
Animal Study: |
|
References |
|
---|
Data from [Data independently produced by , , Cancer Lett, 2018, 439:78-90]
VEGFA expression in the indicated cells treated with or without bevacizumab or transfected with VEGFA or shVEGFA.
Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth [ Nat Commun, 2024, 15(1):1359] | PubMed: 38355578 |
Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins [ Front Immunol, 2024, 15:1273280] | PubMed: 38533506 |
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway [ Front Oncol, 2024, 14:1302850] | PubMed: 38420012 |
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 11(2):986-1000] | PubMed: 38234115 |
Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis [ ESC Heart Fail, 2024, 10.1002/ehf2.14640] | PubMed: 38234115 |
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade [ Cancer Immunol Res, 2023, 11(11):1493-1507] | PubMed: 37728484 |
L1CAM promotes vasculogenic mimicry formation by miR-143-3p-induced expression of hexokinase 2 in glioma [ Mol Oncol, 2023, none] | PubMed: 36708044 |
Vascularized Immunocompetent Patient-Derived Tumor Model to Predict Treatment Response for Lung Cancer Patients [ iScience, 2023, Volume 26, Issue 10] | PubMed: none |
In vitro vascularized immunocompetent patient-derived model to test cancer therapies [ iScience, 2023, 26(10):108094] | PubMed: 37860774 |
In vitro vascularized immunocompetent patient-derived model to test cancer therapies [ iScience, 2023, 26(10):108094] | PubMed: 37860774 |
FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.
Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.